Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead

Immuneering Corp

Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.
Net loss Q4 2023 $15.1M ($0.52 per share); full year net loss $53.5M ($1.88 per share).
FDA Fast Track designation for IMM-1-104 in pancreatic cancer received Feb 2024.
Topline Phase 1 data for IMM-1-104 expected March 2024; first patient in Phase 2a expected March 2024.
First patient dosing in Phase 1/2a trial of IMM-6-415 expected March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immuneering Corp reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-24-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.